|Day's Range||32.54 - 36.82|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||23.45|
|Dividend & Yield||1.02 (3.16%)|
|1y Target Est||N/A|
The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.
Roche Holding said revenue rose in the first quarter, thanks to strong sales of several of its drugs.
India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.